Display Settings:

Format

Send to:

Choose Destination
We are sorry, but NCBI web applications do not support your browser and may not function properly. More information
    Nat Rev Drug Discov. 2012 Feb 1;11(2):89-90. doi: 10.1038/nrd3659.

    (Mis)treating the pharmacogenetic incidentalome.

    Source

    Harvard Medical School Center for Biomedical Informatics, 10 Shattuck Street, Boston, Massachusetts 02115, USA. isaac_kohane@harvard.edu

    Abstract

    Genome-wide screening is anticipated to accelerate the development of personalized medicine by identifying and exploiting new associations between genomic variants and drug responses. However, this goal could be undermined if care is not taken to minimize the impact of pharmacogenomic associations that turn out to have narrower implications than suggested by initial studies.

    PMID:
    22293554
    [PubMed - indexed for MEDLINE]

      Supplemental Content

      Icon for Nature Publishing Group

      Save items

      Recent activity

      Your browsing activity is empty.

      Activity recording is turned off.

      Turn recording back on

      See more...
      Write to the Help Desk